## **News Releases**

All Years

Search

Go

Advanced Search

NOV 13, 2020 Inhibrx Reports Financial Results for the Third Quarter 2020 and Announces Amended Loan Agreement with Oxford

NOV 11, 2020 Inhibrx Announces Positive Interim Results from the Phase 1 Trial of INBRX-109 in Chondrosarcoma Patients

## NOV 5, 2020

Inhibrx Announces Participation in Upcoming Investor and Scientific Conferences

AUG 21, 2020 Inhibrx Announces Closing of Initial Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

AUG 18, 2020 Inhibrx Announces Pricing of Initial Public Offering of Common Stock

JAN 8, 2020 Inhibrx Announces Dosing of First Patient in Phase 1 Dose-Escalation Study of INBRX-106, a Novel Hexavalent Agonist of OX40


## SEP 4, 2019 Inhibrx Announces Enrollment of First Patient in Phase 1 Study of INBRX-101, a Modified Recombinant Human AAT-Fc Fusion Protein

SEP 3, 2019 Inhibrx Reports Phase 1 Dose Escalation Results of INBRX-109, a Multivalent Agonist of Death Receptor 5

MAY 30, 2019 Inhibrx Announces Option Agreement for Development and Commercialization of INBRX-101 (AAT-Fc) Outside of the United States and Canada with Chiesi Group

MAY 21, 2019 Inhibrx Announces \$40M Investment from Viking Global Investors

Show 10 🗸 per page





https://inhibrx.investorroom.com/news-releases?l=10&o=50